PRINCIPAL INVESTIGATOR

POSTDOCTORAL RESEARCHERS:

• Cristina Martín Higueras (“Juan de la Cierva” investigator, MICINN)

PHD STUDENTS AND TRAINEES:

• Ignacio Alonso de Vega (Studentship programme for training research personnel for PhD thesis, ACIISI)
• Isabel Betancor Fernández (PhD student, ULL)
• Celeste González García (PhD student, ULL)

TECHNICAL AND ADMINISTRATIVE STAFF:

• Bárbara Rodríguez Rodríguez (CIBER of rare diseases)

RESEARCH LINES:

We are interested in the molecular basis of inherited metabolic disorders and orphan diseases, such as Type I Primary Hyperoxaluria. For these studies we design and develop appropriate animal models to test the potential therapeutic effects of active molecules.

FUNDED PROJECTS:

• Molecular substrate reduction therapy for primary hyperoxaluria (SAF2015-69796-C2-1-R – “Terapia molecular de reducción de substrato para la hiperoxaluria primaria”). PI: Eduardo Salido Ruiz. Ministry of Science and innovation (2016-2019, 157,300 €)
• In vivo screening based on the reversal of cellular phenotypes to find new drugs inhibiting the Chk1 kinase involved in cancer. Project Agustín de Betancourt – “Rastreo in vivo basado en la reversión de fenotipo celular para encontrar nuevos fármacos inhibidores contra la quinasa Chk1 implicada en cáncer”. PI: David Gillespie, Tutor: Eduardo Salido Ruiz Tenerife Regional Government (2017-2021, 160,000 €)
• Gene editing service. “Agustín de Betancourt” Project. PI: Belinda Rivero Pérez; PI-ULL: Eduardo Salido Ruiz. Council of Tenerife (2020-2023, 160,000 €)
• Amendment NO.1 Master Consulting Agreement (Biomarin Pharmaceutical. 2017-2020, 30.000$). PI: Eduardo Salido Ruiz
• Material Transfer Agreement (Uniqure Biopharma. 2018 – present, 28,800 €). PI: Eduardo Salido Ruiz
• Material Transfer Agreement (Biomarin Pharmaceutical. 2015-2020, 55,000 €). PI: Eduardo Salido Ruiz

PUBLICATIONS 2019:

• Kukreja A, Lasaro M, Cobaugh C, Forbes C, Tang J-P, Gao X, Martin-Higueras C, Pey AL, Salido E, Sobolov S, Subramanian RR. Systemic Alanine Glyoxylate Aminotransferase mRNA Improves Glyoxylate Metabolism in a Mouse Model of Primary Hyperoxaluria Type 1. Nucleic Acid Ther. 2019 Apr;29(2):104-113. doi: 10.1089/nat.2018.0740
• Medina-Carmona E,Betancor-Fernández I,Santos J,Mesa-Torres N,Grottelli S, Batlle C,Naganathan AN,Oppici E,Cellini B,Ventura S,Salido E,Pey AL. Insight into the specificity and severity of pathogenic mechanisms associated with missense mutations through experimental and structural perturbation analyses. Hum Mol Genet. 2019 Jan 1;28(1):1-15. doi: 10.1093/hmg/ddy323
• Medina Vega L,Hernández Nieto L,Salido Ruiz E,Álvarez-Argüelles Cabrera H, Raya Sánche JM. Comprehensive clinical, molecular and histopathological analysis of bone marrow in chronic myeloproliferative neoplasia [Análisis integrado clínico, molecular e histopatológico de la médula ósea en las neoplasias mieloproliferativas crónicas]. Rev Clin Esp. 2019 Nov;219(8):440-444. doi: 10.1016/j.rce.2018.11.012
• Garrelfs SF, Rumsby G, Peters-Sengers H, Erger F, Groothoff JW, Beck BB, Oosterveld MJS, Pelle A, Neuhaus T, Adams B, Cochat P, Salido E, Lipkin GW, Hoppe B, Hulton SA; OxalEurope Consortium. Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up. Kidney Int. 2019 Dec;96(6):1389-1399. Kidney Int. 2019 Dec;96(6):1389-1399. doi: 10.1016/j.kint.2019.08.018
• Martinez-Turrillas R, Rodriguez-Diaz S, Rodriguez-Marquez P, Martin-Mallo A, Salido E, Beck BB, Prosper F, Rodriguez-Madoz JR. Generation of an induced pluripotent stem cell line (CIMAi001-A) from a compound heterozygous Primary Hyperoxaluria Type I (PH1) patient carrying p.G170R and p.R122* mutations in the AGXT gene. Stem Cell Res. 2019 Dec;41:101626. doi: 10.1016/j.scr.2019.101626
• Vankova P, Salido E, Timson DJ, Man P, Pey AL. A Dynamic Core in Human NQO1 Controls the Functional and Stability Effects of Ligand Binding and Their Communication across the Enzyme Dimer. Biomolecules. 2019 Nov 12;9(11). pii: E728. doi: 10.3390/biom9110728
• Gonzalez-Sanchez L, Cobos-Fernandez MA, Lopez-Nieva P, Villa-Morales M, Stamatakis K, Cuezva JM, Marin Rubio JL, Vazquez-Dominguez I, Gonzalez-Vasconcellos I, Salido E, Llamas P, Lopez-Lorenzo JL, Santos J, Fernandez-Piqueras J. Exploiting the passenger ACO1-deficiency arising from 9p21 deletions to kill T-cell lymphoblastic neoplasia cells. Carcinogenesis. 2019 Nov 17. pii: bgz185. doi: 10.1093/carcin/bgz185. [Epub ahead of print]
• Martin-Higueras C, Ludwig-Portugall I, Hoppe B, Kurts C. Targeting kidney inflammation as a new therapy for primary hyperoxaluria? Nephrol Dial Transplant. 2019 Jun 1;34(6):908-914. doi: 10.1093/ndt/gfy239

OTHER SELECTED PUBLICATIONS FROM THE LAST 10 YEARS:

• Martin-Higueras C, Luis-Lima S, Salido E. Glycolate oxidase is a safe and efficient target for substrate reduction therapy in a mouse model of Primary Hyperoxaluria Type I. Mol Ther. 2016 Apr;24(4):719-25. doi: 10.1038/mt.2015.224
• García-Gómez S, Reyes A, Martínez-Jiménez MI, Chocrón ES, Mourón S, Terrados G, Powell C, Salido E, Méndez J, Holt IJ, Blanco L. PrimPol, an archaic primase/polymerase operating in human cells. Mol Cell. 2013 Nov 21;52(4):541-53
• Salido E, Pey AL, Rodriguez R, Lorenzo V. Primary hyperoxalurias: Disorders of glyoxylate detoxification. Biochim Biophys Acta. 2012 Sep;1822(9):1453-64. doi: 10.1016/j.bbadis.2012.03.004
• Salido E, Rodriguez-Pena M, Santana A, Beattie SG, Petry H, Torres A. Phenotypic Correction of a Mouse Model for Primary Hyperoxaluria with Adenoassociated Virus Gene Transfer. Mol Ther. 2011 May;19(5):870-5. doi: 10.1038/mt.2010.270
• Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanchi SA, Yap HK, Saleem M, Zhang Q, Nikolic B, Chaudhuri A, Daftarian P, Salido E, Torres A, Salifu M, Sarwal MM, Schaefer F, Morath C, Schwenger V, Zeier M, Gupta V, Roth D, Rastaldi MP, Burke G, Ruiz P, Reiser J. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med. 2011 Jul 31;17(8):952-60. doi: 10.1038/nm.2411